サウスダコタにおける非小細胞肺癌の臨床試験
サウスダコタ内の拠点で、非小細胞肺癌に関する20件の研究が参加者を募集しています。
サウスダコタ内の都市
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT04267848A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Avera Medical Group, Sioux Falls
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Sanford Cancer Center ( Site 3266), Sioux Falls
- Avera Cancer Institute ( Site 3209), Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07513376Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Avera Saint Luke's Hospital, Aberdeen
- Avera Cancer Institute, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Sanford Cancer Center ( Site 0053), Sioux Falls
- Avera Cancer Institute- Research ( Site 0090), Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312137Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Avera Cancer Institute- Research, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Sioux Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Avera Cancer Institute, Sioux Falls
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT04613596KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Sanford Cancer Center ( Site 0038), Sioux Falls
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/25更新 · NCT04165798KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Sanford Cancer Center ( Site 0038), Sioux Falls
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT04165070A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Sanford Cancer Center ( Site 0038), Sioux Falls
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06731907A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Sanford Cancer Center, Sioux Falls
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/06/26更新 · NCT04614103Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Rapid City Regional Hospital, Rapid City
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Monument Health Rapid City Hospital, Rapid City
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。